Source comparison
CJC-1295 with DAC vs without DAC — Which Works Better?
Research using CJC-1295 with DAC reported plasma growth hormone (GH) elevation lasting 7–14 days after a single injection. But when comparing outcomes to no-DAC variants in controlled studies, peak amplitude dropped by 40–60%. The DAC (Drug Affinity Complex) m
This comparison does not assign a generated winner or score.
- Research using CJC-1295 with DAC reported plasma growth hormone (GH) elevation lasting 7–14 days after a single injection. But when comparing outcomes to no-DAC variants in controlled studies, peak amplitude dropped by 40–60%. The DAC (Drug Affinity Complex) modification extends peptide half-life by binding to endogenous albumin, creating a sustained-release mechanism that fundamentally alters the pharmacokinetic profile. The trade-off: you lose the sharp pulsatile GH spikes that mirror natural somatotroph secretion, which some hypothesize may carry distinct metabolic or anabolic signalling advantages.
- Our team has worked with researchers evaluating both variants across protocols spanning body composition studies, metabolic intervention trials, and tissue repair investigations. The question isn't which peptide is objectively superior. It's which pharmacokinetic profile aligns with your experimental design and dosing constraints.
- What's the core difference between CJC-1295 with DAC and without DAC?
- CJC-1295 with DAC (also called Modified GRF 1-29) binds to serum albumin via a lysine-maleimide attachment, extending plasma half-life to approximately 6–8 days and sustaining elevated GH levels for up to two weeks per injection. CJC-1295 without DAC (standard Modified GRF 1-29) has a half-life of roughly 30 minutes, requiring multiple daily administrations but preserving physiological pulsatile GH release patterns that more closely mimic endogenous somatotroph activity.
- Here's what that actually means for study design: with-DAC protocols require weekly or biweekly injections, making them logistically simpler for long-duration trials. Without-DAC protocols demand 2–3 daily injections but allow researchers to time GH pulses around specific intervention windows. Meals, training sessions, sleep architecture studies, or circadian rhythm investigations. The DAC variant creates a pharmacological steady-state that erases natural pulsatility; the no-DAC variant amplifies existing pulses without fundamentally altering their temporal structure. This article breaks down the precise mechanisms behind each modification, validated dosing ranges from published trials, and practical protocol considerations that determine which peptide fits your research question.